Thiamazole

Verify with FDA CVM →

623 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
623
Total Reports
52
Deaths Reported
830.0%
Death Rate

Active Ingredients

Thiamazole

Administration Routes

OralUnknownTransdermalTopicalOtherAuricular (Otic)Intradermal

Species Affected

Cat 565
Unknown 38
Human 18
Dog 2

Most Affected Breeds

Domestic Shorthair 372
Cat (unknown) 73
Domestic Longhair 64
Unknown 56
Siamese 17
Maine Coon 11
Ragdoll 8
Russian 4
Cat (other) 4
Burmese 2

Most Reported Reactions

Vomiting 142
Weight loss 108
Lethargy (see also Central nervous system depression in 'Neurological') 69
Elevated alanine aminotransferase (ALT) 66
Lack of efficacy - NOS 49
Anorexia 47
Decreased appetite 45
Other abnormal test result NOS 37
Excoriation 35
Elevated blood urea nitrogen (BUN) 35
Low thyroxine (T4) 32
Pruritus 31

Outcome Breakdown

Outcome Unknown
332 (56.5%)
Recovered/Normal
163 (27.7%)
Ongoing
39 (6.6%)
Died
28 (4.8%)
Euthanized
24 (4.1%)
Recovered with Sequela
2 (0.3%)

Data Summary

Metric Value
Total adverse event reports 623
Reports involving death 52
Case-fatality rate (reported events) 830.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Thiamazole Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 623 adverse event reports referencing Thiamazole, including 52 reports in which the animal died — a 830.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Thiamazole. Reported administration routes include Oral, Unknown, Transdermal, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Thiamazole reports are Cat (565 reports), Unknown (38 reports), Human (18 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (372), Cat (unknown) (73), Domestic Longhair (64) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Thiamazole are Vomiting (142), Weight loss (108), Lethargy (see also Central nervous system depression in 'Neurological') (69), Elevated alanine aminotransferase (ALT) (66). Of the 588 reports with a coded outcome, Outcome Unknown is the leading category at 56.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Thiamazole.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial